Phathom Pharmaceuticals, Inc.
PHAT
$3.31
$0.165.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 81.86M | 55.25M | 26.27M | 9.92M | 2.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 81.86M | 55.25M | 26.27M | 9.92M | 2.59M |
| Cost of Revenue | 11.27M | 7.97M | 4.33M | 1.97M | 593.00K |
| Gross Profit | 70.59M | 47.28M | 21.95M | 7.95M | 2.00M |
| SG&A Expenses | 323.13M | 290.66M | 270.98M | 218.27M | 161.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 368.24M | 332.72M | 314.20M | 262.71M | 209.78M |
| Operating Income | -286.38M | -277.47M | -287.93M | -252.79M | -207.19M |
| Income Before Tax | -345.79M | -334.33M | -339.45M | -297.11M | -246.63M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -345.79 | -334.33 | -339.45 | -297.11 | -246.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -345.79M | -334.33M | -339.45M | -297.11M | -246.63M |
| EBIT | -286.38M | -277.47M | -287.93M | -252.79M | -207.19M |
| EBITDA | -285.62M | -276.67M | -287.14M | -252.07M | -206.55M |
| EPS Basic | -5.24 | -5.35 | -5.69 | -5.13 | -4.41 |
| Normalized Basic EPS | -3.28 | -3.35 | -3.56 | -3.21 | -2.76 |
| EPS Diluted | -5.24 | -5.35 | -5.69 | -5.13 | -4.41 |
| Normalized Diluted EPS | -3.28 | -3.35 | -3.56 | -3.21 | -2.76 |
| Average Basic Shares Outstanding | 266.20M | 252.60M | 238.85M | 231.01M | 220.95M |
| Average Diluted Shares Outstanding | 266.20M | 252.60M | 238.85M | 231.01M | 220.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |